Added benefit of nalmefene not confirmed for alcohol dependence Indirect comparison is difficult to interpret because of differences in patients and treatment goals Nalmefene has been approved since February 2013 for people with alcohol dependence who currently drink a lot of alcohol, but who don’t have physical withdrawal symptoms and who usually do not require immediate detoxification. The German Institute for Quality and Effectiveness in HEALTHCARE examined in a dossier assessment whether the drug offers an added benefit over the correct comparator therapy in this affected person group. According to the findings, this added benefit isn’t confirmed: In its dossier, the drug manufacturer only provided data for an indirect assessment with the correct comparator therapy naltrexone http://kamagrafrance.eu/la-dysfonction-erectile-et-le-diabete.html .
In multi-middle, placebo-controlled, double-blind, randomized Stage III clinical trials, Clonicel demonstrated statistical significance when used to take care of ADHD. Related StoriesNovo Nordisk announces FDA acceptance of Tresiba for diabetes treatmentAllergan settles patent litigation with Amneal related to NAMENDA XR extended discharge capsulesMylan announces U.S. Clonicel can be an important product in our pediatric pipeline, and we are excited about the potential advantage that Clonicel might provide to children and adolescents who’ve ADHD. In stage III medical trials, Clonicel demonstrated an improvement in an aggregate of 18 ADHD symptoms recognized by the American Psychiatric Association and utilized by doctors to diagnose and classify ADHD in children and adolescents..